STRC Research

Misha-Hearing-10-Year-Plan

2 min read

Sequence: Misha’s Hearing — From Diagnosis to 10-Year Strategy

TL;DR: STRC gene mutation → progressive SNHL → gene therapy likely available 2030-2035. Strategy: document current hearing now, join research networks, stay connected to cochlear implant pathway as fallback. Act now on things that have long lead times.

An argument chain from diagnosis to action.

Reading Order

  1. STRC Hearing Loss — STRC gene: what it does, why it causes SNHL, prognosis ↓ The mechanism is clear. What does the research trajectory look like?…
  2. Central Auditory Processing and Hearing Loss (Brain) — Auditory pathway: from cochlea to cortex, where STRC damage occurs ↓ Damage is at the hair cell level — this is where gene therapy targets…
  3. Sound Therapy and Hearing Loss — Sound therapy limitations and opportunities for SNHL ↓ Therapy helps with processing, not the underlying cause…
  4. Misha-Hearing-10-Year-Plan — The strategy: document, network, position for therapy window ↓ What’s the cognitive/educational picture while we wait?…
  5. Gut-Brain Axis and Neurodevelopment — Systemic health affects hearing outcomes and neurodevelopment ↓ Applied: microbiome, diet, inflammation all matter for hearing preservation…

The Argument

STRC-related SNHL has a 10-year horizon for gene therapy that is now scientifically credible:

  • STRC gene causes stereocilin deficiency → outer hair cell dysfunction → progressive loss
  • Gene therapy targeting hair cells is in active research (multiple labs, first trials likely 2028-2032)
  • Window: document audiograms now (baseline), connect with research networks now, stay current on cochlear implant candidacy
  • Parallel track: optimize systemic health (gut-brain, inflammation, diet) — these affect hearing preservation rate

The 10-year plan is not passive waiting. It’s active positioning.

Connections

Graph View

Backlinks